Overview

Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HCP1007 capsules and Rosuvastatin plus Omega-3.
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Treatments:
Rosuvastatin Calcium